| FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies |
20 |
| Neoadjuvant Treatment for Pancreatic Cancer |
19 |
| Electrochemotherapy of superficial tumors - Current status: Basic principles, operating procedures, shared indications, and emerging applications |
19 |
| Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib |
16 |
| Systemic treatment of pancreatic cancer revisited |
16 |
| Clinical applications of proton and carbon ion therapy |
14 |
| Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy |
12 |
| Nutritional status and clinical outcomes in pediatric patients with solid tumors : A systematic review of the literature |
12 |
| Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer |
11 |
| Significance of TIM3 expression in cancer: From biology to the clinic |
11 |
| Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications |
11 |
| New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs |
11 |
| Cancer immunotherapy-associated hypophysitis |
10 |
| Nimotuzumab: beyond the EGFR signaling cascade inhibition |
9 |
| A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients |
9 |
| Current therapeutic options in metastatic castration-resistant prostate cancer |
9 |
| Aging, immune senescence, and immunotherapy: A comprehensive review |
9 |
| Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors |
9 |
| Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years |
9 |
| GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy |
8 |
| Modern radiotherapy for head and neck cancer |
8 |
| Ionizing radiation effects on the tumor microenvironment |
8 |
| Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy |
6 |
| Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease |
6 |
| Acute promyelocytic leukemia and variant fusion proteins: PLZF-RAR alpha fusion protein at a glance |
6 |
| Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver |
6 |
| CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation |
6 |
| Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology |
6 |
| An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine |
6 |
| Normal tissue complication probability (NTCP) models for modern radiation therapy |
5 |
| Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy |
5 |
| State of the science in smoldering myeloma: Should we be treating in the clinic? |
4 |
| Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly |
4 |
| Management of immunotherapy toxicities in older adults |
4 |
| Selecting chemotherapy for pancreatic cancer: Far away or so close? |
4 |
| PET/CT in radiation oncology |
4 |
| Technological evolution of radiation treatment: Implications for clinical applications |
4 |
| Charged particle beams to cure cancer: Strengths and challenges |
4 |
| Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes |
3 |
| HeberFERON, a new formulation of IFNs with improved pharmacodynamic Perspective for cancer treatment |
3 |
| CIMAvax-EGF: Toward long-term survival of advanced NSCLC |
3 |
| Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside |
3 |
| Relationship between food behavior and taste and smell alterations in cancer patients undergoing chemotherapy: A structured review |
3 |
| Primary mediastinal germ cell tumors |
3 |
| Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study |
3 |
| Healthcare professionals' attitudes toward cancer precision medicine: A systematic review |
3 |
| Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma |
2 |
| Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers |
2 |
| Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab |
2 |
| A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy |
2 |
